EPISODE · Feb 6, 2017 · 14 MIN
February 2017: Spironolactone - potion or poison?
from DTB Podcast · host BMJ Group
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of hyperkalaemia associated with spironolactone in people with heart failure. They consider recent advice issued by the Medicines and Healthcare products Regulatory Agency and highlight the importance of regular monitoring of potassium and renal function. The editors also review the evidence for daclizumab, a drug for relapsing multiple sclerosis, and provide a brief introduction to the rationale and methods of qualitative research in health care.
What this episode covers
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of hyperkalaemia associated with spironolactone in people with heart failure. They consider recent advice issued by the Medicines and Healthcare products Regulatory Agency and highlight the importance of regular monitoring of potassium and renal function. The editors also review the evidence for daclizumab, a drug for relapsing multiple sclerosis, and provide a brief introduction to the rationale and methods of qualitative research in health care.
NOW PLAYING
February 2017: Spironolactone - potion or poison?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m